| scholarly article | Q13442814 |
| P50 | author | Marco Matucci-Cerinic | Q19859583 |
| Maya Hema Buch | Q44940582 | ||
| Eugene Joseph Kucharz | Q66419555 | ||
| P2093 | author name string | Yannick Allanore | |
| Hendrik Schulze-Koops | |||
| Arthur Kavanaugh | |||
| Arnd Schwebig | |||
| Johann Poetzl | |||
| Heike Woehling | |||
| Goran Babic | |||
| Adanna Davis | |||
| P2860 | cites work | ACR/EULAR 2010 rheumatoid arthritis classification criteria | Q26864171 |
| A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 | ||
| Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
| The Functional Assessment of Cancer Therapy scale: development and validation of the general measure | Q34361336 | ||
| Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
| Etanercept: An overview | Q35190102 | ||
| Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison | Q35637985 | ||
| A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study | Q37206622 | ||
| Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products | Q37321197 | ||
| A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy | Q37604518 | ||
| GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes | Q37695053 | ||
| Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis | Q44003346 | ||
| The Health Assessment Questionnaire (HAQ). | Q46944131 | ||
| State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015. | Q50098933 | ||
| Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. | Q51051064 | ||
| The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psori | Q51359715 | ||
| A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. | Q53170870 | ||
| Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately respondin | Q54967818 | ||
| Measurement of patient outcome in arthritis | Q56879288 | ||
| Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e | Q63101754 | ||
| The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis | Q68109843 | ||
| Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system | Q73206828 | ||
| A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis | Q73235899 | ||
| Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes | Q74455180 | ||
| Biosimilars-why terminology matters | Q84709013 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | e000757 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | RMD open | Q27726913 |
| P1476 | title | Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA | |
| P478 | volume | 4 |
| Q91944393 | A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis |
| Q90083372 | Biosimilars versus biologics for inflammatory conditions |
| Q89600836 | Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis |
| Q92771591 | Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis |
| Q64922356 | Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, doubl |
Search more.